You are here: start » group_3_presentation_3_-_plaque_psoriasis

Differences

This shows you the differences between two versions of the page.

--- group_3_presentation_3_-_plaque_psoriasis [2017/04/07 22:30]
makdayr
+++ group_3_presentation_3_-_plaque_psoriasis [2018/01/25 15:18] (current)
@@ Line 3: / Line 3: @@
 ====== Presentation 3: Plaque Psoriasis Powerpoint File ======
-<HTML>
+{{:psoriasis_slides.pdf|}}
-<br>
-</HTML>
 ====== Introduction ======
@@ Line 15: / Line 13: @@
 {{:pi1.png|}}
-   Figure: Plaque psoriasis
+   Figure 1: Plaque psoriasis
 Image from: http://jamanetwork.com/journals/jama/fullarticle/1104805
 </style>
@@ Line 44: / Line 42: @@
 {{:screen_shot_2017-04-06_at_1.18.11_pm.png|}}
-   Figure: A typical psoriatic plaque
+   Figure 2: A typical psoriatic plaque
 Image from: http://www.wikipedia.com
 {{:screen_shot_2017-04-06_at_1.23.58_pm.png|}}
-   Figure: A red and scaly scalp lesion
+   Figure 3: A red and scaly scalp lesion
 Image from: http://nopsoriasis.net
 </style>
@@ Line 79: / Line 77: @@
 {{:screen_shot_2017-04-06_at_1.16.39_pm.png|}}
-   Figure: Ranking the severity of psoriasis, via PASI
+   Figure 4: Ranking the severity of psoriasis, via PASI
 Image from: http://www.healthline.com
 </style>
@@ Line 113: / Line 111: @@
  {{:psor_eti_.png|}}
-   Figure: The genetic linkage of plaque psoriasis
+   Figure 5: The genetic linkage of plaque psoriasis
 Image from: https://www.slideshare.net/Gurpgork/psoriasis-35245580
@@ Line 139: / Line 137: @@
 {{:patho_psor.png|}}
-   Figure: Cytokine networks in psoriasis
+   Figure 6: Cytokine networks in psoriasis
 Image from: http://www.nature.com/nature/journal/v445/n7130/abs/nature05663.html
 </style>
@@ Line 179: / Line 177: @@
 This is supported by the results of a systemic analysis conducted by Lowe et al., which compared psoriasis improvement rates in patients treated with either dithranol or a corticosteroid. The researchers concluded that corticosteroids are most effective when used for short-term flares, and dithralin was best used for chronic treatment of the disease (Lowe et al., 1984).
+**Systemic Agents**
+Systemic agents are prescription drugs that affect the entire body. Most patients prescribed these agents will have moderate to severe psoriasis and/or psoriatic arthritis. Systemic medications are also used by those who are not responsive to or are unable to use topical medications or ultraviolet (UV) light treatment (Feldman, 2013).
+These drugs are taken by mouth in liquid or pill form or given by injection into the skin or muscle or through intravenous (IV) infusion (Feldman, 2013).
+//Methotrexate//
+This drug is in a class of medications known as antimetabolites and is typically only used in moderate to severe cases of psoriasis (Feldman, 2013). Its mechanism of action involves immunosuppression, in which T-cells are deactivated in order to decrease the autoimmune response to epidermal cells (Felman, 2013). It is usually taken orally, either in pill or liquid form, but can be taken via IV (Mayo Clinic, 2015). There are risks surrounding long-term use of methotrexate, including severe liver damage or the decreased production of white and red blood cells or blood platelets (Mayo Clinic, 2015).
+//Cyclosporine//
+This drug is used for adults with severe psoriasis and otherwise normal immune systems. It suppresses the activity of T-cells within the immune system, which slows the growth of skin cells (Feldman, 2013). Cyclosporine is typically taken orally in 3 to 5 mg/kg per day with symptom relief within 4 weeks (Feldman, 2013). Since this drug is suppressing your immune system, this increases the patient’s chances of infection or related health problems. There are risks with taking the medication in high doses or for long-term use and these include, high blood pressure or kidney ailments (Mayo Clinic, 2015).
+//Soriatane (acitretin)//
+This drug is an oral retinoid, which is a synthetic form of vitamin A and usually prescribed to those with severe cases of psoriasis (Feldman, 2013). Retinoids help control the multiplication of cells, including the speed with which skin cells grow and shed, which increases in psoriasis (Mayo Clinic, 2015). The dose ranges of acitretin can be anywhere from 25 mg every other day to 50 mg daily (Feldman, 2013). Acitretin can also be prescribed in combination with UVA or PUVA therapy; shown to increase response rates (Feldman, 2013). The use of this medication may put one at risk of lip inflammation or hair loss. Those who are or may become pregnant should also be wary of this medication as it has been shown to elicit birth defects in pregnant women (Mayo Clinic, 2015).
 **__MANAGEMENT__**
@@ Line 223: / Line 239: @@
 ====== References ======
+Boros, M., Kemény, Á., Sebők, B., Bagoly, T., Perkecz, A., Petőházi, Z., ... & Helyes, Z. (2013). Sulphurous medicinal waters increase somatostatin release: it is a possible mechanism of anti-inflammatory effect of balneotherapy in psoriasis. European Journal of Integrative Medicine, 5(2), 109-118.
 Burke, A. (2017). Plaque Psoriasis. Retrieved from http://jamanetwork.com/journals/jama/fullarticle/1104805
 Dogra, S., & Mahajan, R. (2016). Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatology Online Journal, 7(6), 471.
+Feldman, S. R., Pearce, D. J., Dellavalle, R. P., & Duffin, K. C. (2013). Treatment of psoriasis. UpToDate. http://www.uptodate.com (accessed April, 2017).
+Fluhr, J. W., Cavallotti, C., & Berardesca, E. (2008). Emollients, moisturizers, and keratolytic agents in psoriasis. Clinics in dermatology, 26(4), 380-386.
 Gudjonsson, J. E., Johnston, A., Sigmundsdottir, H., & Valdimarsson, H. (2004). Immunopathogenic mechanisms in psoriasis. Clinical & Experimental Immunology, 135(1), 1-8.
@@ Line 233: / Line 254: @@
 Jain, S. (2012). Dermatology: illustrated study guide and comprehensive board review. Springer Science & Business Media.
+Kemeny, L., Ruzicka, T., & Braun-Falco, O. (1990). Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacology and Physiology, 3(1), 1-20.
 Langley, R. G., Krueger, G. G., & Griffiths, C. E. M. (2005). Psoriasis: epidemiology, clinical features, and quality of life. Annals of the rheumatic diseases, 64(suppl 2), ii18-ii23.
 Lew, W., Bowcock, A. M., & Krueger, J. G. (2004). Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and ‘Type 1’inflammatory gene expression. Trends in immunology, 25(6), 295-305.
+Lowe, N. J., Ashton, R. E., Koudsi, H., Verschoore, M., & Schaefer, H. (1984). Anthralin for psoriasis: Short-contact anthralin therapy compared with topical steroid and conventional anthralin. Journal of the American Academy of Dermatology, 10(1), 69-72.
 Lowes, M. A., Bowcock, A. M., & Krueger, J. G. (2007). Pathogenesis and therapy of psoriasis. Nature, 445(7130), 866-873.
 Mak, R. K. H., Hundhausen, C., & Nestle, F. O. (2009). Progress in understanding the immunopathogenesis of psoriasis. Actas dermo-sifiliograficas, 100, 2-13.
+Mason, A. R., Mason, J., Cork, M., Dooley, G., & Edwards, G. (2009). Topical treatments for chronic plaque psoriasis. The Cochrane Library.
+Matz, H. (2010). Phototherapy for psoriasis: what to choose and how to use: facts and controversies. Clinics in dermatology, 28(1), 73-80.
+Menter, A., Gottlieb, A., Feldman, S. R., Van Voorhees, A. S., Leonardi, C. L., Gordon, K. B., ... & Beutner, K. R. (2008). Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. Journal of the American Academy of Dermatology, 58(5), 826-850.
 Nestle, F., Kaplan, D., & Barker, J. (2009). Psoriasis. New England Journal Of Medicine, 361(5), 496-509. http://dx.doi.org/10.1056/nejmra0804595
@@ Line 251: / Line 282: @@
 Parrish, L. (2012). Psoriasis: symptoms, treatments and its impact on quality of life. British journal of community nursing, 17(11), 524-528.
+Peroni, A., Gisondi, P., Zanoni, M., & Girolomoni, G. (2008). Balneotherapy for chronic plaque psoriasis at Comano spa in Trentino, Italy. Dermatologic therapy, 21(s1), S31-S38.
 “Plaque Psoriasis Pictures”. Healthline. Retrieved 2017-03-29.
 “Psoriasis Symptoms and Triggers”. WebMD. Retrieved 2017-03-29.
+Psoriasis: Treatment and Drugs. (2015). Mayo Clinic. http://www.mayoclinic.org (accessed April, 2017).
 Raychaudhuri, S. K., Maverakis, E., & Raychaudhuri, S. P. (2014). Diagnosis and classification of psoriasis. Autoimmunity reviews, 13(4), 490-495.
@@ Line 261: / Line 296: @@
 Smith, C. H., & Barker, J. N. W. N. (2006). Psoriasis and its management. BMJ: British Medical Journal, 333(7564), 380.
+Ucak, S., Ekmekci, T. R., Basat, O., Koslu, A., & Altuntas, Y. (2006). Comparison of various insulin sensivity indices in psoriatic patients and their relationship with type of psoriasis. Journal of the European Academy of Dermatology and Venereology, 20(5), 517-522.
+Uva, L., Miguel, D., Pinheiro, C., Antunes, J., Cruz, D., Ferreira, J., & Filipe, P. (2012). Mechanisms of action of topical corticosteroids in psoriasis. International journal of endocrinology, 2012.
+Wolters, M. (2005). Diet and psoriasis: experimental data and clinical evidence. British Journal of Dermatology, 153(4), 706-714.

Differences

Search

Navigation

Print/export

Tools

QR Code